Oral Desmopressin Composition With Preservative-Buffer Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a stable desmopressin oral liquid formulation that maintains efficacy over time and is suitable for pediatric use without requiring dilution.
Innovation Solution
A dual-functional preservative-buffer system comprising benzoic acid and sodium benzoate, or other acidic preservatives and their salts, is used to stabilize desmopressin in an oral solution, maintaining stability at room temperature for at least 2 months and ensuring bioequivalence to existing formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If desmopressin is formulated as an oral liquid, then ease of administration is improved, but stability is worsened
Solution Approach 1:
The patent introduces a dual-functional preservative-buffer system (benzoic acid/sodium benzoate) as an intermediary substance that mediates between the conflicting requirements of liquid formulation and stability. This system acts as a buffer to maintain pH and as a preservative to prevent degradation, enabling the liquid formulation to remain stable without requiring refrigeration or complex packaging.
Solution Approach 2:
The patent changes the chemical parameters of the formulation by selecting specific concentrations of benzoic acid (0.03-0.04% w/v) and sodium benzoate (0.16-0.32% w/v) that create an optimal pH environment for desmopressin stability. This parameter optimization allows the liquid formulation to maintain stability at room temperature while remaining easy to administer.
2Reliability
If desmopressin oral liquid is prepared without preservatives, then purity is improved, but stability is worsened
Solution Approach 1:
The benzoic acid/sodium benzoate system serves as a benign intermediary that protects the purity of desmopressin by preventing microbial contamination and chemical degradation. These preservatives are selected because they are pharmaceutically acceptable and do not significantly interact with or degrade the active ingredient, thus maintaining purity while providing stability.
Solution Approach 2:
The patent uses low concentrations of preservatives (total preservative system at 0.19-0.36% w/v) that are sufficient for short-to-medium term stability (at least 2 months at room temperature) but do not require long-term potency. This approach accepts minimal preservative presence in exchange for room temperature stability without compromising clinical efficacy.
3Stability of the object's composition
If buffer concentration is increased to maintain pH, then stability is improved, but impurity formation is worsened
Solution Approach 1:
The patent optimizes the buffer concentration parameters to a narrow range (0.16-0.32% w/v sodium benzoate) that provides sufficient pH buffering capacity to maintain stability while minimizing the risk of impurity formation. This precise parameter control ensures the buffer is strong enough to prevent degradation but weak enough to avoid generating harmful byproducts.
Solution Approach 2:
The benzoic acid/sodium benzoate system acts as a mild intermediary buffer that maintains pH without causing significant impurity formation. Unlike stronger buffers that might react with desmopressin, this weak buffer system provides sufficient pH control (maintaining stability) while minimizing chemical interactions that could generate impurities.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a stable, ready-to-use oral desmopressin formulation that retains efficacy and bioavailability, suitable for pediatric use, with minimal impurity formation and no need for dilution, and maintains stability over extended storage periods.
Implementation Method 1
a two-component, dual-functional, preservative-buffer system
Implementation Method 2
a two-component, dual-functional, preservative-buffer system comprising an acidic preservative and a salt of the acidic preservative
Data Source
AI summary
Provided herein are desmopressin oral liquid formulations. Also provided herein are methods of making and using desmopressin oral liquid compositions for the treatment of certain diseases including diabetes insipidus, enuresis, hemophilia A, von willebrand disease, high blood urea levels and others.